These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30475421)

  • 1. Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease.
    Bruchfeld A; Lindahl K
    Semin Dial; 2019 Mar; 32(2):135-140. PubMed ID: 30475421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis.
    Fabrizi F; Donato FM; Messa P
    Int J Artif Organs; 2017 Oct; 40(10):531-541. PubMed ID: 28708211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease.
    Maruyama A; Partovi N; Yoshida EM; Erb SR; Azalgara VM; Hussaini T
    Nephrol Dial Transplant; 2017 Jan; 32(1):35-41. PubMed ID: 26481484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel treatments for hepatitis C virus infection in chronic kidney disease].
    Fabrizi F; Messa P
    G Ital Nefrol; 2016; 33(4):. PubMed ID: 27545640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C Treatment in Chronic Kidney Disease Patients: The Kidney Disease Improving Global Outcomes Perspective.
    Jadoul M; Martin P
    Blood Purif; 2017; 43(1-3):206-209. PubMed ID: 28114144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Direct-acting antiviral agents, hepatitis C and dialysis: an update].
    Fabrizi F; Lampertico P; Messa P
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?
    Fabrizi F; Messa P
    Expert Rev Clin Pharmacol; 2015; 8(6):785-93. PubMed ID: 26365524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".
    Pol S; Parlati L
    Liver Int; 2018 Feb; 38 Suppl 1():28-33. PubMed ID: 29427485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.
    Li T; Qu Y; Guo Y; Wang Y; Wang L
    Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C and Treatment in Patients with Chronic Kidney Disease.
    Jalota A; Lindner BK; Thomas B; Lerma EV
    Dis Mon; 2021 Feb; 67(2):101017. PubMed ID: 32553421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Hepatitis C Virus Infection in Dialysis Patients.
    Kikuchi K
    Contrib Nephrol; 2018; 196():119-122. PubMed ID: 30041215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.
    Cacoub P; Desbois AC; Isnard-Bagnis C; Rocatello D; Ferri C
    J Hepatol; 2016 Oct; 65(1 Suppl):S82-S94. PubMed ID: 27641990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
    Sorbera MA; Friedman ML; Cope R
    J Pharm Pract; 2017 Jun; 30(3):359-365. PubMed ID: 26902648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summary of the 2018 Kidney Disease Improving Global Outcomes (KDIGO) Guideline on hepatitis C in chronic kidney disease.
    Gordon CE; Balk EM; Francis JM
    Semin Dial; 2019 Mar; 32(2):187-195. PubMed ID: 30496617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and important drug-drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti-viral therapy.
    Cohen E; Liapakis A
    Semin Dial; 2019 Mar; 32(2):141-151. PubMed ID: 30557903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hepatitis C: Results in real life.
    Hézode C
    Liver Int; 2018 Feb; 38 Suppl 1():21-27. PubMed ID: 29427481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
    Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
    J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
    Fabrizi F; Martin P; Messa P
    Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.
    Majumdar A; Kitson MT; Roberts SK
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1276-92. PubMed ID: 27087015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.